{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T07:46:15.036932+00:00","company":{"ticker":"ICU","cik":1831868,"company_name":"SeaStar Medical Holding Corp"},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"f31aca6d423e6b10a3c530e4503f4810e3bc64f8","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-08-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-31","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until January 27, 2026 (the “Compliance Date”), to regain compliance","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-103356","anchor_url":"https://secwatch.observer/filing/0000950170-25-103356#claim-f31aca6d423e6b10a3c530e4503f4810e3bc64f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025103356/0000950170-25-103356-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c2e9aee7ff6a228d233f94a7395610ce9e2dde29","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-08-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-31","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"SeaStar Medical Holding Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 31, 2025, SeaStar Medical Holding Corporation (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-25-103274","anchor_url":"https://secwatch.observer/filing/0000950170-25-103274#claim-c2e9aee7ff6a228d233f94a7395610ce9e2dde29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025103274/0000950170-25-103274-index.htm"},{"fact_type":"executive_change","fact_key":"5b99ddc88e","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bernadette N. Vincent was elected as Director at SeaStar Medical Holding Corp.","evidence_excerpt":"the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0000950170-24-071087","anchor_url":"https://secwatch.observer/filing/0000950170-24-071087#claim-5b99ddc88e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024071087/0000950170-24-071087-index.htm"},{"fact_type":"executive_change","fact_key":"3d2147ba53","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jennifer A. Baird was elected as Director at SeaStar Medical Holding Corp.","evidence_excerpt":"the Company issued a press release announcing the appointment of John Neuman and the two newly elected members to the Board, Ms. Jennifer A. Baird, and Ms. Bernadette N. Vincent.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0000950170-24-071087","anchor_url":"https://secwatch.observer/filing/0000950170-24-071087#claim-3d2147ba53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024071087/0000950170-24-071087-index.htm"},{"fact_type":"executive_change","fact_key":"7c94c7ebf4","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-05","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John Neuman was appointed as Class I Director at SeaStar Medical Holding Corp.","evidence_excerpt":"the Board of Directors (the Board\") of SeaStar Medical Holding Corporation (the \"Company\") appointed Mr. John Neuman as a Class I director, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-071087","anchor_url":"https://secwatch.observer/filing/0000950170-24-071087#claim-7c94c7ebf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024071087/0000950170-24-071087-index.htm"},{"fact_type":"executive_change","fact_key":"b75bac5132","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-05","interim":false,"role":"Director","role_category":"director","successor_name":"John Neuman","successor_named":true},"claim":"Andres Lobo resigned as Director at SeaStar Medical Holding Corp.","evidence_excerpt":"Mr. Andres Lobo informed the Board that he will resign as a director of the Company, effective as of June 5, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-071087","anchor_url":"https://secwatch.observer/filing/0000950170-24-071087#claim-b75bac5132","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024071087/0000950170-24-071087-index.htm"},{"fact_type":"earnings_release","fact_key":"09d2e1127fa9645bc62294ae2801f7fc771dde56","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"SeaStar Medical Holding Corp reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter-ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-059518","anchor_url":"https://secwatch.observer/filing/0000950170-24-059518#claim-09d2e1127fa9645bc62294ae2801f7fc771dde56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/0000950170-24-059518-index.htm"},{"fact_type":"governance_change","fact_key":"cd786b3d235593bc241699c484e1783a0c25161f","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-04-18T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-04-12","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to reduce stockholder quorum threshold from majority to 33 1/3% and remove 'Acting in Concert' provisions."},"claim":"SeaStar Medical Holding Corp: Amended and restated bylaws to reduce stockholder quorum threshold from majority to 33 1/3% and remove 'Acting in Concert' provisions (effective 2024-04-12).","evidence_excerpt":"On April 12, 2024, the Board of Directors (the “Board”) of SeaStar Medical Holding Corporation (the “Company”) approved the amendment and restatement of the Company’s Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”) to, among other things: • reduce the quorum threshold for meetings of stockholders from the holders of a majority of the common stock of the Company issued and outstanding and entitled to vote to the holders of at least 33 1/3% of the common stock of the Company issued and outstanding and entitled to vote; and • remove the “Acting in Concert” definition and provisions","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000929638-24-001521","anchor_url":"https://secwatch.observer/filing/0000929638-24-001521#claim-cd786b3d235593bc241699c484e1783a0c25161f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000092963824001521/0000929638-24-001521-index.htm"},{"fact_type":"earnings_release","fact_key":"66ef5a3d5f1b3a9f6eaac432109803916792b81a","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-04-17T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the 12 months ended December 31, 2023","report_date":"2024-04-17","result_type":"reported_results","revenue_text":null},"claim":"SeaStar Medical Holding Corp reported financial results for the 12 months ended December 31, 2023.","evidence_excerpt":"SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER (April 17, 2024) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000929638-24-001513","anchor_url":"https://secwatch.observer/filing/0000929638-24-001513#claim-66ef5a3d5f1b3a9f6eaac432109803916792b81a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm"},{"fact_type":"auditor_change","fact_key":"399fd377556967626ba3db2751598558b964a882","cik":1831868,"ticker":"ICU","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-03-27T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":null,"disagreement_text":null,"effective_date":"2024-03-21","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"SeaStar Medical Holding Corp reported that prior financial statements should not be relied upon.","evidence_excerpt":"On March 21, 2024, after discussion with the Company’s management, the Audit Committee determined that a restatement of the Company’s audited financial statements for the fiscal year ended December 31, 2022 and unaudited interim financial statements for the fiscal quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 would be appropriate","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-036837","anchor_url":"https://secwatch.observer/filing/0000950170-24-036837#claim-399fd377556967626ba3db2751598558b964a882","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024036837/0000950170-24-036837-index.htm"}]}